HCPCS Level II code J0801 denotes an injection of corticotropin (Acthar Gel), billed per unit (up to 40 units). Nationally, this code matters because corticotropin is a high-cost, specialty biologic used for select inflammatory, autoimmune, and rare disease indications; accurate coding affects coverage determinations, prior authorization workflows, and cost reporting. Key payers for national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of clinical context, typical sites of service (outpatient clinic, physician office, ambulatory infusion center), and the implications for billing teams and revenue cycle operations. The publication outlines common modifiers in use and typical payer interactions, and it provides benchmarks and policy considerations where available. It also highlights areas where payers may require documentation or prior authorization and summarizes coding nuances relevant to billing accuracy and claims adjudication.

Data not available in the input are noted where applicable. This piece is intended as a national reference to support coding clarity and payer engagement on claims involving corticotropin administration under J0801.